Bausch Health Companies Inc. filings document regulatory disclosures for a global diversified pharmaceutical company incorporated in British Columbia. The record includes Form 8-K reports for quarterly and annual operating results, Regulation FD updates, clinical-program disclosures, material agreements, debt exchanges and credit-agreement refinancing involving Bausch Health and its subsidiaries, including Bausch + Lomb.
Proxy materials describe annual meeting matters, director elections, auditor approval, executive compensation votes and governance procedures. Other current reports address compensatory arrangements, including performance share unit settlement terms, and capital-structure disclosures tied to senior secured notes, guarantees, collateral arrangements and refinancing transactions.
Bausch Health Companies Inc. is soliciting shareholder votes for its 2026 virtual annual meeting on May 19, 2026 at 9:00 a.m. Eastern. Shareholders will elect ten directors for one-year terms, cast an advisory vote on 2025 executive compensation, appoint PricewaterhouseCoopers LLP as auditor through the 2027 meeting, and receive the audited 2025 financial statements.
The board is largely independent, with nine of ten nominees meeting independence standards, and board gender representation is expected to rise to 40% if all nominees are elected. The company details director share ownership guidelines, committee structure, risk oversight, and ESG priorities, including information security, carbon and energy initiatives, and employee health, safety and development.
Bausch Health Companies Inc. director Sandra Leung received an equity compensation award in the form of Restricted Share Units for her board service for the quarter ending March 31, 2026. She acquired 5,946 common shares at a deemed price of $5.40 per share, bringing her direct holdings to 44,354 common shares.
Bausch Health Companies Inc. director John Paulson reported an equity compensation grant rather than an open-market trade. He acquired 11,574 common share equivalents at $5.40 per share as Restricted Share Units issued in lieu of cash fees for his board service for the quarter ending March 31, 2026.
After this award, he holds 371,694 common shares directly and has an additional 73,255,869 shares reported as indirectly owned by managed funds. A footnote states these securities are directly owned by the funds, and Paulson disclaims beneficial ownership except to the extent of any pecuniary interest.
Bausch Health Companies Inc. director Amy B. Wechsler received an equity-based compensation award for Board service. She acquired 1,273 Restricted Share Units issued in lieu of cash compensation for the quarter ending March 31, 2026, each representing a contingent right to receive one common share. Following this grant, she directly holds 267,714 common shares, including the awarded units.
Bausch Health Companies Inc. executive vice president and CFO Jean-Jacques Charhon reported a tax-related share disposition. On the vesting of Restricted Share Units, 49,060 common shares at $5.93 per share were withheld to cover tax obligations, a non-market transaction. After this withholding, Charhon directly holds 706,478 common shares.
Bausch Health Companies Inc. EVP and General Counsel Seana Carson reported several equity transactions in the company’s common shares. She sold 6,856 shares on March 2, 2026 at $5.78 per share and 4,420 shares on March 3, 2026 at $5.77 per share in open-market sales under a pre-arranged Rule 10b5-1 trading plan. The filing also shows share dispositions used to cover tax withholding on vesting of restricted share units, and a cash settlement of 137,922 previously earned performance share unit awards under the company’s 2014 Omnibus Incentive Plan. After the most recent sale, Carson directly holds 616,761 common shares of Bausch Health.
Bausch Health Companies Inc. director and CEO Thomas Appio reported equity award-related transactions in common shares, no par value. On February 27, 2026 and March 2, 2026, the company withheld 83,093 and 83,705 shares, respectively, to satisfy tax withholding obligations upon vesting of restricted share units.
The filing also records an "other" transaction for 1,137,862 performance share unit awards that will be settled in cash rather than company stock, as approved by the board committee and previously disclosed. Following these transactions, Appio directly held 3,453,236 common shares on March 2, 2026.
BHC reported a Form 144 notice for proposed sales of common stock by an insider. The filing lists two sale transactions by Seana Carson: 8,388 shares on 02/27/2026 for $49,908.60 and 6,856 shares on 03/02/2026 for $39,627.68.
The filing also shows 4,420 shares tied to restricted stock vesting on 03/02/2026 labeled as Issuer / Compensation. The record lists a brokerage account at Fidelity Brokerage Services LLC.
Bausch Health Companies Inc. updated how certain 2023 performance share units (PSUs) for two senior executives will be paid out. These PSUs were granted in March 2023, tied to a three-year performance period, and are scheduled to vest on March 3, 2026.
For CEO Thomas Appio, the award agreement covering 1,137,862 2023 PSUs was amended so that, at vesting, the earned PSUs will be settled solely in cash equal to the market price of Bausch Health common shares, using the closing price on the vesting date. For executive Lisa Carson, an agreement provides that she will irrevocably surrender her 137,922 2023 PSUs in exchange for a cash amount based on the same market price definition.
The company notes that full details of the Appio and Carson agreements will be included as exhibits to its Form 10‑Q for the quarter ending March 31, 2026.
BHC reported a Form 144 notice indicating a proposed sale of 6,856 common shares through Fidelity Brokerage Services LLC on 03/02/2026 for exchange listing NYSE. The filing also shows a recent disposition of 8,388 common shares on 02/27/2026 for $49,908.60.